After a median follow-up of 30 months, 24 patients have relapsed in the G-CHL arm and 3 patients have relapsed in the IB arm; 17 patients required a subsequent treatment in the G-CHL arm (14 BTK inhibitors and 3 venetoclax ± rituximab) and 2 patients in the IB arm (both venetoclax ± rituximab); 10 patients died (4 due to sepsis, 2 due to pneumonia, 2 due to CLL, and 2 due to cardiovascular events) in the G-CHL arm vs. 8 in the IB arm (3 due to cardiovascular events, 1 due to RS, 1 due to pneumonia, 1 due to sepsis, 1 due to lung cancer, and 1 due to unknown cause). Here, BTK is linked to susceptibility to pneumonia measurement.